Literature DB >> 21570960

Association of apoliprotein E polymorphisms and metabolic syndrome in subjects with extreme obesity.

D C Ferreira1, T F Costa, S L F Aguiar, A R S Marques, S A Ramos, K B Gomes, J I Alvarez-Leite.   

Abstract

BACKGROUND: Obesity has been linked to metabolic syndrome (MS), which increases the risk of cardiovascular disease (CVD). Polymorphisms of Apolipoprotein E have also been associated with increased CVD risk. Therefore, this study investigated the association between MS and Apo E polymorphisms.
METHODS: We measured anthropometric and biochemical variables and determined the Apo E genotype of 147 grade III obese patients.
RESULTS: The percentage of female subjects was 86.4%. The mean age and BMI of the subjects were 41 years and 53.5 kg/m(2), respectively. MS had been diagnosed in 79% of the subjects. The proportions of those exhibiting MS risk factors were as follows: 100% had a high BMI, 80% had hypertension, 65% had low levels of high-density lipoprotein (HDL), 38% had diabetes, and 39% had hypertriglyceridemia. We found five genotypes for which the allelic distribution was different in the MS group compared to the general population. The ε4 allele was more frequent in the group with neither MS nor hypertension.
CONCLUSIONS: The morbidly obese patients exhibited a higher incidence of MS and a different allelic distribution when compared with other populations. The ε4 allele was associated with the absence of MS and hypertension.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570960     DOI: 10.1016/j.cca.2011.04.035

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome: the National Heart, Lung and Blood Institute Family Heart Study.

Authors:  Lana Y H Lai; Andrew B Petrone; James S Pankow; Donna K Arnett; Kari E North; R Curtis Ellison; Steven C Hunt; James L Rosenzweig; Luc Djoussé
Journal:  Diabetes Metab Res Rev       Date:  2015-04-06       Impact factor: 4.876

Review 2.  Beyond the CNS: The many peripheral roles of APOE.

Authors:  Ana B Martínez-Martínez; Elena Torres-Perez; Nicholas Devanney; Raquel Del Moral; Lance A Johnson; Jose M Arbones-Mainar
Journal:  Neurobiol Dis       Date:  2020-02-19       Impact factor: 5.996

3.  Diversity of apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of metabolic syndrome among hypertensive patients.

Authors:  Andrei Alkmim Teixeira; Mauro Sergio Marrocos; Beata Marie Redublo Quinto; Maria Aparecida Dalboni; Cassio Jose de Oliveira Rodrigues; Silmara de Melo Carmona; Mariana Kuniyoshi; Marcelo Costa Batista
Journal:  Lipids Health Dis       Date:  2014-11-20       Impact factor: 3.876

4.  APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome.

Authors:  Rosalind Fallaize; Andrew L Carvalho-Wells; Audrey C Tierney; Carmen Marin; Beata Kieć-Wilk; Aldona Dembińska-Kieć; Christian A Drevon; Catherine DeFoort; José Lopez-Miranda; Ulf Risérus; Wim H Saris; Ellen E Blaak; Helen M Roche; Julie A Lovegrove
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

5.  Association between APOE polymorphism and metabolic syndrome in Uyghur ethnic men.

Authors:  YuPing Sun; Rong Wei; DanDan Yan; FeiLi Xu; XiaoJin Zhang; Bei Zhang; Delixiati Yimiti; Hui Li; HongYan Sun; Cheng Hu; Li Luo; Hua Yao
Journal:  BMJ Open       Date:  2016-01-06       Impact factor: 2.692

6.  In the Heart of the Amazon: Noncommunicable Diseases and Apolipoprotein E4 Genotype in the Riverine Population.

Authors:  Gabriela P F Arrifano; Jacqueline I Alvarez-Leite; José Rogério Souza-Monteiro; Marcus Augusto-Oliveira; Ricardo Paraense; Barbarella M Macchi; André Pinto; Reinaldo B Oriá; José Luiz Martins do Nascimento; Maria Elena Crespo-Lopez
Journal:  Int J Environ Res Public Health       Date:  2018-09-07       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.